PROPANC BIOPHARMA INC
COM NEW · CUSIP 74346N701
0
institutional holders
-6 vs Q1 2026
—reported value*
0 new
0 added
0 reduced
6 sold out
net sold ≈ $48.7k (-462.4k shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable.
Trends to Q2 2026
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2025 | 3 |
| Q4 2025 | 5 |
| Q1 2026 | 6 |
| Q2 2026 | 0 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2025 | 3 | 2 |
| Q1 2026 | 5 | 4 |
| Q2 2026 | 0 | 6 |
Biggest buyers
| None |
Biggest sellers
| UBS Group AG | Sold out | -182.6k |
| JANE STREET GROUP, LLC | Sold out | -143.2k |
| Marex Group Ltd | Sold out | -67.7k |
| Virtu Financial LLC | Sold out | -40.7k |
| Sassicaia Capital Advisers LLC | Sold out | -16.0k |
| XTX Topco Ltd | Sold out | -12.1k |
Holders, Q2 2026
| Manager | Shares | Change |
|---|